Gyre Therapeutics (GYRE) Free Cash Flow (2016 - 2025)
Historic Free Cash Flow for Gyre Therapeutics (GYRE) over the last 17 years, with Q3 2025 value amounting to $4.0 million.
- Gyre Therapeutics' Free Cash Flow rose 28402.71% to $4.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.9 million, marking a year-over-year increase of 23004.04%. This contributed to the annual value of -$6.0 million for FY2024, which is 13427.91% down from last year.
- As of Q3 2025, Gyre Therapeutics' Free Cash Flow stood at $4.0 million, which was up 28402.71% from $1.9 million recorded in Q2 2025.
- In the past 5 years, Gyre Therapeutics' Free Cash Flow ranged from a high of $42.3 million in Q4 2022 and a low of -$24.4 million during Q1 2021
- In the last 5 years, Gyre Therapeutics' Free Cash Flow had a median value of -$251000.0 in 2025 and averaged -$3.0 million.
- As far as peak fluctuations go, Gyre Therapeutics' Free Cash Flow soared by 33929.62% in 2022, and later plummeted by 43798.64% in 2024.
- Over the past 5 years, Gyre Therapeutics' Free Cash Flow (Quarter) stood at -$17.7 million in 2021, then skyrocketed by 339.3% to $42.3 million in 2022, then plummeted by 97.55% to $1.0 million in 2023, then plummeted by 359.94% to -$2.7 million in 2024, then soared by 247.31% to $4.0 million in 2025.
- Its Free Cash Flow stands at $4.0 million for Q3 2025, versus $1.9 million for Q2 2025 and -$251000.0 for Q1 2025.